Trial ID or NCT#

NCT02091141

Status

recruiting iconRECRUITING

Purpose

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Official Title

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

James Ford
James Ford
Medical oncologist, Gastrointestinal specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Hans-Christoph Becker, MD, FSABI, FSCCT
Radiologist
Clinical Professor, Radiology

Contact us to find out if this trial is right for you.

CONTACT

Ivy Lau
(650) 721-8899